Litcius/Paper detail

Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

Kim Papp, Jacek C. Szepietowski, Leon Kircik, Darryl Toth, Lawrence F. Eichenfield, Donald Y.M. Leung, Seth Forman, May E. Venturanza, Kang Sun, Michael E. Kuligowski, Eric L. Simpson

2021Journal of the American Academy of Dermatology298 citationsDOI

Topics & Concepts

MedicineAtopic dermatitisRuxolitinibEczema Area and Severity IndexClinical endpointRandomized controlled trialDermatologyInternal medicineBone marrowMyelofibrosisDermatology and Skin DiseasesFood Allergy and Anaphylaxis ResearchDrug-Induced Adverse Reactions
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies | Litcius